Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bufei Huoxue Capsules is a Traditional Chinese Medicine (TCM) formulation developed and manufactured by Changshu Leiyunshang Pharmaceutical. It is an NMPA-approved pharmaceutical product in China, primarily indicated for the treatment of chronic respiratory conditions such as Chronic Obstructive Pulmonary Disease (COPD) and chronic bronchitis, particularly in patients exhibiting Qi deficiency and blood stasis. The formulation is composed of three key botanical ingredients: *Astragalus membranaceus* (Huangqi), *Paeonia lactiflora* (Baishao), and *Psoralea corylifolia* (Buguzhi). Its therapeutic mechanism is characterized by tonifying the lung Qi, nourishing the blood, and activating blood circulation to resolve stasis, thereby improving pulmonary function and reducing clinical symptoms like cough and dyspnea. It has also been investigated for its potential role in managing pulmonary fibrosis and supporting recovery from respiratory infections.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bufei huoxue capsules.